Law360, New York ( February 26, 2016, 10:27 AM EST) -- In its Feb. 22, 2016 unanimous panel decision in the Loestrin 24 Fe Antitrust Litigation,[1] the U.S. Court of Appeals for the First Circuit became the second federal appellate court since the U.S. Supreme Court's seminal decision in Federal Trade Commission v. Actavis[2] to wrestle with the knotty problem of "reverse payment" settlements of Hatch-Waxman Act-related[3] pharmaceutical patent infringement claims.[4] Although the court of appeals sought to limit its decision to a narrow legal question, the reader familiar with this growing body of litigation might take five points away from the decision....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.